Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-24-108796
Filing Date
2024-09-23
Accepted
2024-09-23 16:55:31
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A revb-20240331.htm   iXBRL 10-Q/A 916092
2 EX-31.1 revb-ex31_1.htm EX-31.1 26732
3 EX-31.2 revb-ex31_2.htm EX-31.2 26791
4 EX-32.1 revb-ex32_1.htm EX-32.1 10368
5 EX-32.2 revb-ex32_2.htm EX-32.2 11047
  Complete submission text file 0000950170-24-108796.txt   5962755

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT revb-20240331.xsd EX-101.SCH 1389957
63 EXTRACTED XBRL INSTANCE DOCUMENT revb-20240331_htm.xml XML 794263
Mailing Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122
Business Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122 650-800-3717
REVELATION BIOSCIENCES, INC. (Filer) CIK: 0001810560 (see all company filings)

EIN.: 843898466 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-39603 | Film No.: 241316759
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)